Real-time PCR has many advantages compared with antigenemia and qualitative PCR assays for detecting cytomegalovirus (CMV) infection in patients following SCT. However, the procedure used in each report was not standardized. This study compares the CMV load detected by real-time PCR assays amplifying distinct genomic regions. Real-time PCR assays based on US17, UL65, immediate early protein (IE) and glycoprotein B(gB) were selected and comparisons were made between each genomic region, and with antigenemia and nested PCR (IE region) in 18 SCT patients. The CMV load detected by real-time PCR using all combinations of primers targeting distinct genomic regions and by antigenemia assays correlated well. However, US17 and UL65-PCR could detect CMV earlier than gB-PCR, antigenemia and nested PCR assays. In longitudinal analysis, gB-PCR demonstrated a trend for showing a lower viral load in some patients than US17-, UL65-and IE-PCR. Moreover, the results suggest that a cutoff level of 500 copies/ml might be used to decide when to initiate treatment. We propose that monitoring should be carried out using real-time PCR assays targeting the US17 region and that a CMV load of 500 copies/ml could be used as a cutoff value for initiating treatment in patients following SCT, receiving immunoglobulin prophylaxis.
real-time PCR
Cytomegalovirus (CMV) is a common pathogen of humans and frequently causes severe and life-threatening diseases in patients following stem cell transplantation (SCT). 1 Since CMV disease occurs in up to 35% of allogeneic bone marrow transplant recipients and carries a high mortality rate despite treatment, 2 early and accurate diagnosis and reliable methods for monitoring CMV infection are essential. The recent development of real-time polymerase chain reaction (PCR) procedures for rapidly quantifying genome load has proved useful for accurate monitoring. Many reports have described the advantages of real-time PCR assays in comparison to antigenemia or qualitative PCR in patients who have undergone SCT. [3] [4] [5] However, some unsolved problems remain, not least that the procedure remains unstandardized. Whereas antigenemia assays have been almost completely standardized using an anti-pp65 antibody, 6, 7 real-time PCR assays have been carried out using a variety of procedures: the target region being amplified by real-time PCR assay differs in each report, some target the immediate early protein (IE), while others target glycoprotein B (gB) or the US17 region, 2, 4, 8 and primers and probes for the target region also differ. 2, 9, 10 Few reports have been published which compare the viral load detected by real-time PCR assay targeting distinct genomic regions.
In addition, real-time PCR assays are likely to be sensitive clinically and there is a need to establish a cutoff point for initiating antiviral therapy. Li et al 4 proposed a CMV viral load of 1000 copies/ml as a cutoff point for initiating antiviral therapy in patients at high risk of CMV disease. However, whether this cutoff point can be applied to patients assessed by real-time PCR assay amplifying a distinct genomic region is debatable because the procedure has not yet been standardized. Moreover, although it has been hypothesized that cell-free viral DNA in plasma could be derived from lysis of CMV-infected cells such as polymorphonuclear leukocytes and endothelial cells, the detailed property of cell-free DNA in plasma remains unclear. 11 Recently, duplex real-time PCR methods have been shown to be superior to single real-time PCR assays. 12 The selection of more sensitive genomic regions in real-time PCR assay is important. Therefore, to provide more data for developing a standard methodology for monitoring and diagnosing CMV reactivation, we decided to compare the viral loads detected by real-time PCR assay amplifying distinct genomic regions. We selected the US17, IE and gB regions, which had previously been used for CMV detection. 2, 4, 8 In addition, we created new primers and probe sets to amplify the late antigen, UL65, which had previously been reported in studies using nucleic acid sequence-based amplification, 13 and compared the viral load indicated by the four genomic regions in patients after SCT. We also compared the results obtained with those from experiments using qualitative nested PCR and antigenemia assays.
Materials and methods

Patients
We selected groups at high risk for CMV infection. Between May 1996 and September 2003, 18 patients who had received unrelated SCT for hematological malignancy and who were shown to be positive more than once by nested PCR or antigenemia assay during a period of at least 90 days post transplantation were enrolled. The characteristics of these patients are shown in Table 1 . There were 11 men and seven women with a median age of 45 years and a range of 23-56 years. The serostatus for CMV of donors and recipients before SCT were as follows: donor positive/ recipient positive results were observed in 16 cases and donor negative/recipient positive in two. In all, 15 patients received SCT from HLA-matched unrelated donors and three patients from HLA-mismatched unrelated donors. All patients were given 1000 mg/day aciclovir orally from days -7 to 35 for the prevention of herpes simplex virus infection and intravenous CMV high-titer immunoglobulin (5 g) at weekly intervals for the first 3 months after SCT. A total of 223 samples were obtained weekly from 18 patients and these were examined by both real-time PCR and nested PCR assays. Of the 223 samples, 210 that were obtained weekly from 17 of the 18 patients were examined by antigenemia assay.
Nested PCR and real-time PCR
Viral DNA was extracted from plasma (0.2 ml) with a QIAamp Blood mini-kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. DNA was eluted from the Qiagen columns in a final volume of 100 ml of distilled water and was stored at À301C until used.
Nested PCR was carried out as previously described. 14 The primers used for PCR were complementary to the IE gene region 1. The outer primer set consisted of MIE-4 (5 0 -CCAAGCGGCCTCTGATAACCAAGCC-3 0 ) and MIE-5 (5 0 -CAGCACCATCCTCCTCTTCTCTGG-3 0 ). The inner primer set consisted of IE-1 (5 0 -CCACCCGTGGTGC CAGCTCC-3 0 ) and IE-2 (5 0 -CCCGCTCCTCCTGAG CACCC-3 0 ). All reaction mixtures used TaKaRa Ex Taq (Takara, Ohtsu, Japan). The primers were purchased from Qiagen.
Real-time PCR was performed as described previously. 14 The design of the PCR primers and a fluorogenic probe were based on each open-reading frame (US17, UL65, IE and gB regions) of CMV AD169 ( Table 2 ). The primers were purchased from Qiagen. The probes were purchased from Applied Biosystems (Tokyo, Japan).
To standardize the quantification, we subcloned part of the open-reading frame into a vector (pGEM-T Easy Vector System (Promega, Madison, USA)). DNA fragments were then amplified with an ABI PRISM 7700 Table 2 Primers and probe set
Reading frame Forward primer Reverse primer
Reading frame Probe Sequence Detection System (Perkin-Elmer Biosystems, Foster City, CA, USA) in a 50 ml reaction mixture, containing 10 ml DNA sample, 25 ml TaqMan Universal PCR master mix (Perkin-Elmer Biosystems), 15 pmol of each primer, and 10 pmol TaqMan probe. Thermal cycling conditions were as follows: 501C for 2 min, 951C for 10 min, and 50 cycles of 951C for 15 s and 611C for 1 min.
Stability of real-time PCR
A standard curve was produced using seven 10-fold dilutions of a plasmid standard covering 10-10 7 plasmid copies per reaction, which corresponded to 5 Â 10 2 -5 Â 10 8 copies/ml of plasma. The standard curve possessed a correlation coefficient of 0.990 with a slope of À3.40 and y-intercept value of 38.50 in US17-PCR. The real-time PCR assay detected between 3.15 and 593 555 copies of CMV genome/ml in 234 samples. The reproducibility was determined from three blood samples. The coefficient of variation (CV) values in US17-PCR obtained for control low (500 copies/well), middle (10 4 copies/well), and high (10 5 copies/well) viral load samples in intra-assay variation testing were 0.23, 0.10, and 0.11, respectively, and in interassay variation testing, the CV values were 1.51, 1.71, and 1.43, respectively. The results of the real-time PCR assays based on other genomic regions were also similar. All measurements in the above tests were conducted in quintuplicate.
Antigenemia assay
Antigenemia assays were conducted with a Teijin antigenemia kit (Teijin, Osaka, Japan) as reported previously.
14 Peripheral blood leukocytes were isolated by dextran sedimentation, and leukocytes were cytocentrifuged on glass slides. The slides were air-dried, fixed with acetone, and then stained with peroxidase-conjugated monoclonal antibody HRP-C7, which specifically binds the pp65 antigen of CMV. The degree of antigenemia was expressed as the number of CMV antigen-positive cells per 5 Â 10 4 leukocytes.
Antiviral therapy with ganciclovir for prevention of CMV disease
The decision to use pre-emptive therapy was based mainly on a positive antigenemia test (X1/50 000 antigen-positive cells). Intravenous infusion of ganciclovir at 10 mg/kg/day was started when more than 1/50 000 antigen-positive cells were detected. Ganciclovir was continued for as long as antigenemia persisted.
Statistical analysis
Differences between two groups were assessed by the Mann-Whitney test or the Wilcoxon signed rank test. Correlations between two groups were analyzed by Spearman's test. P-values less than 0.05 were considered statistically significant.
Results
Correlations between the real-time PCR assays amplifying distinct genomic regions and the antigenemia assay and nested PCR A total of 223 weekly samples were obtained from 18 patients and were examined by real-time PCR assays based on distinct genomic regions (US17-, UL65-, IE-and gB-PCR). The CMV DNA copy number obtained from all combinations of two distinct real-time PCR assays correlated well (Po0.0001) (Figure 1 ). Of the 223 weekly samples, 210 that were obtained from 17 of the 18 patients were examined by antigenemia assay. The correlation between the pp65-positive cell count by antigenemia assay and the CMV DNA copy number by each real-time PCR assay was also statistically significant (Po0.0001). The viral loads detected by real-time PCR and nested PCR assays were investigated using 223 samples obtained from 18 patients. The viral load detected by each genomic region using real-time PCR assay in the group assessed as CMVpositive by the nested PCR assay was significantly higher than in the group assessed as negative (Po0.0001).
Sensitivity and specificity of viral load as determined by real-time PCR
In order to define the optimal cutoff value of CMV viral load for initiating antiviral therapy, receiver-operating characteristic (ROC) curve analysis was performed, using the antigenemia assay as the reference standard. We investigated the sensitivity and specificity for each cutoff value of CMV DNA when a level of X1/50 000 CMV antigen-positive cells by the antigenemia assay was used as the reference standard. If a CMV DNA level of 500 copies/ ml was used as a cutoff value, the sensitivity and specificity of the US17-PCR assay were 80.7 and 79.1%, respectively. The sensitivity and specificity of the UL65 and IE-PCR assays were also similar. In the gB-PCR assay, the sensitivity and specificity were 61.4 and 90.9% respectively, when a CMV DNA level of 500 copies/ml was used as a cutoff value. The sensitivity and specificity were 77.1 and 80.0%, respectively, when a CMV DNA level of 200 copies/ ml was used as a cutoff value. The optimal cutoff value of CMV DNA load was 500 copies/ml in the US17, UL65, and IE-PCR assays, but 200 copies/ml in the gB-PCR assay by ROC curve analysis (Figure 2) .
Comparison of early detection between real-time PCR and antigenemia or nested PCR assays
We investigated whether the results obtained from real-time PCR using each primer and probe set, antigenemia assay, and nested PCR assay showed any discrepancies with respect to early detection of CMV infection. The interval following transplantation that was assessed as positive in different assays was demonstrated (Table 3) . When the cutoff value in real-time PCR was defined as more than 200 copies/ml, US17-and UL65-PCR showed samples to be positive prior to antigenemia or nested PCR in more than 75% of patients. IE-PCR showed samples to be positive prior to antigenemia in 37.5% of patients and to nested PCR in 58.8% of patients, and simultaneously to antigenemia in 56.3% of patients and to nested PCR in 23.5%. gB-PCR showed samples to be positive prior to antigenemia in 31.3% of patients and to nested PCR in 58.8% of patients, and simultaneously to antigenemia in 56.3% of patients and to nested PCR in 29.4%. When the cutoff value of real-time PCR was defined as more than 500 copies/ml, US17-and UL65-PCR showed samples to be positive prior to antigenemia and nested PCR in more than 50.0% of patients. However, IE-PCR showed samples to be positive prior to antigenemia in 37.5% of patients and to nested PCR in 58.8%, and simultaneously to antigenemia in 56.3% of patients and to nested PCR in 23.5%. gB-PCR showed samples to be positive prior to antigenemia in 31.3% of patients and to nested PCR in 37.5%, and simultaneously to antigenemia in 31.3% of patients and to nested PCR in 37.5%.
Comparison for early detection among real-time PCR assays using primers to distinct genomic regions
We compared the day that the first positive result was obtained using real-time PCR assays (Table 4) . When the cutoff value was defined as more than 200 copies/ml, US17-PCR detected CMV infection earliest in 13 cases, UL65-PCR in 11 cases, IE-PCR in four cases, and gB-PCR in five cases. When the cutoff value was defined as more than 500 copies/ml, US17-PCR detected CMV infection earliest in 12 cases, UL65-PCR in 10 cases, IE-PCR in five cases, and gB-PCR in four cases. Using the Wilcoxon signed rank test, US17-PCR and UL65-PCR could detect CMV infection significantly earlier than IE-PCR or gB-PCR when the cutoff value was defined as more than 200 copies/ ml (US17 vs IE; P ¼ 0.008, US17 vs gB; P ¼ 0.02, UL65 vs IE; P ¼ 0.005, UL65 vs gB; P ¼ 0.01). Moreover, US17-PCR and UL65-PCR could detect CMV infection significantly earlier than gB-PCR when the cutoff value was defined as more than 500 copies/ml (US17 vs gB; P ¼ 0.004, UL65 vs gB; P ¼ 0.02). US17-PCR could detect CMV infection significantly earlier than IE-PCR (US17 vs IE; P ¼ 0.004). When the data were analyzed by median or Simultaneously indicated that real-time PCR and antigenemia assays became positive at the same day. The upper numbers indicated the positive and total patient numbers when the cutoff value in real-time PCR was defined as more than 200 copies/ml. The lower numbers indicated the positive and total patient numbers when the cutoff value in real-time PCR was defined as more than 500 copies/ml. The numbers indicate the interval from transplantation to the first positive day. The cutoff point of antigenemia assay was established as 1/50 000 cell. neg indicates negative results. NE indicates to not examinated. Bold face type indicated the day that the first positive result was obtained.
mean, US17-PCR and UL65-PCR could detect CMV infection significantly earlier (from 7 to 10 days) than IE-PCR and gB-PCR (Po0.05). In addition, US17, UL65-PCR could detect CMV infection significantly earlier (from 7 to 10 days) than antigenemia or nested PCR assay even when the cutoff value was defined as more than 500 copies/ml (Po0.05).
Longitudinal analysis
Longitudinal analysis of six patients with high CMV DNA copy numbers is shown in Figure 3 . The CMV DNA copy number detected by real-time PCR using each of the four primers and probe sets were closely paralleled (patient 1-6). The CMV DNA dynamics pattern determined by each realtime PCR assay was well in line with the outcome of the antiviral therapy. However, there was a trend towards gB-PCR showing a lower CMV copy number than US17-, UL65-, and IE-PCR (patient 1, 4-6), especially in patients 4 and 5; gB-PCR showed approximately a 10-fold lower CMV DNA copy number than US17-, UL65-, and IE-PCR. Moreover, treatment was required over a long period (30-60 days) when patients (patients 2-6) initiated antiviral therapy with a CMV copy number of more than 10 000 copies/ml. When the CMV reactivation was analyzed according to the development of acute GVHD (grade II-IV), acute GVHD developed in 12/18 patients (66.7%). Prednisolone was administrated in 13/18 patients (72.2%) for therapy of acute GVHD or other complication. In Figure 3 , grade II-IV acute GVHD developed in patients 1, 2, and 5. Prednisolone was administrated in patients 1, 2, and 5. The Real-time PCR based on distinct regions J Ikewaki et al disease recurred in one patient (patient 4) after treatment was stopped. Using real-time PCR amplifying distinct genomic regions and antigenemia assay, it was not possible to detect the CMV viral load and the antigen-positive cells, respectively, and nested PCR also identified as negative when ganciclovir was stopped. Following recurrence of the disease, US17 and UL65-PCR could detect CMV infection earlier (1 week) than IE-PCR, antigenemia, and nested PCR assays when the cutoff value was defined as more than 500 copies/ml. The CMV loads detected by gB-PCR assay increased to more than 500 copies/ml 2 weeks after the antigenemia assay became positive.
Discussion
The aim of this study was to ascertain whether there was a discrepancy between CMV viral loads detected by real-time PCR amplifying distinct target regions and to establish the most suitable genomic region for monitoring using realtime PCR assay and the cutoff value for initiating antiviral therapy.
We investigated the correlation between real-time PCR and antigenemia assays. The viral loads obtained from each real-time PCR assay correlated well with antigen-positive cells obtained from antigenemia assays. Moreover, the viral load detected using primers to each genomic region, assessed by real-time PCR carried out on the group assessed as CMV-positive by the nested PCR assay, was significantly higher than for the group assessed as negative. This confirmed results published previously.
3,5 Moreover, we investigated the correlation between the CMV viral loads obtained from real-time PCR amplifying a distinct genomic region. Results for all combinations of genomic regions correlated well. Tanaka et al 15 reported that US17-PCR showed a higher (approximately three--10-fold) viral load than IE-PCR. But this trend was not demonstrated in our study. In Tanaka's study, the reaction mixtures, including the volume of DNA, was different for US17-and IE-PCR. This could significantly affect the results. We carried out these experiments keeping the conditions the same throughout, and using a TaqMan Universal PCR master mix.
We then researched the differences found using real-time PCR amplifying distinct genomic regions. We looked at the differences in early detection and longitudinal analysis to clarify the differences shown by these distinct regions. When the cutoff value was defined as more than 200 copies/ ml, US17-and UL65-PCR could detect CMV infection earlier than IE-PCR or gB-PCR. When the cutoff value was defined as more than 500 copies/ml, US17-and UL65-PCR could detect CMV infection earlier than gB-PCR. When analyzed using median or mean values, US17-PCR and UL65-PCR could detect CMV infection significantly earlier (from 7 to 10 days) than IE-PCR and gB-PCR. In the longitudinal analysis, all results obtained from real-time PCR assays amplifying distinct genomic regions were similar. The response to antiviral therapy was also similar. But there were discrepancies in the maximum viral loads detected. In particular, gB-PCR tended to show lower viral loads than US17-, UL-65, and IE-PCR. We demonstrated discrepancies among viral loads detected by real-time PCR assays with respect to early detection and longitudinal analysis. This might result from the heterogeneity of the CMV genome. Yun et al 10 reported that some samples were positive when the real-time PCR assay was targeting a certain region, but negative when another region was targeted and suggested that CMV variation causing mismatching among clinical isolates may substantially decrease the quantification efficiency of the PCR. Moreover, in a previous study, nucleotide sequence comparisons were performed on a highly heterogeneous region (UL region) of three human cytomegalovirus strains. The US region has been reported to be well preserved among several CMV strains. 16 US17-PCR was shown to be more sensitive than the other real-time PCR assays in our study. CMV strains may be categorized into four different groups on the basis of gB genotype and into three different groups on the basis of IE genotype 17, 18 and each genotype based on gB was reported to be equipped with different clinical characteristics. 19 Herrmann et al 12 reported that discrepant copy numbers for pol and gB by real-time PCR were found for samples from two patients and corresponding CMV strains were mismatched at four nucleotide positions compared with the gB fragment primer sequences. This heterogeneity might influence our finding that US17-PCR is more sensitive than IE-and gB-PCR, as the heterogeneity could alter the binding efficiency of the primers and probes.
The cutoff point for initiating antiviral therapy is one of the major problems of monitoring CMV using real-time PCR assays. Many reports propose more than 200 copies/ ml as a suitable cutoff point. 5, 20 However, this cutoff point was defined according to the sensitivity limit of real-time PCR assays and there is the potential risk that patients could be overtreated, resulting in unnecessary drug side effects and unnecessary cost. Our analysis suggests that CMV viral loads of 500 copies/ml might prove a more suitable cutoff point for initiating antiviral therapy in patient groups at high risk of CMV disease using the ROC curve, as real-time PCR targeting US17-and UL65-PCR can detect CMV infection earlier than antigenemia and nested PCR assays. However, early detection of CMV by real-time PCR targeting IE and gB regions does not appear to be better than by antigenemia and nested PCR assays when the cutoff point is defined as more than 500 copies/ml. In addition, real-time PCR assays may not remain advantageous over antigenemia and nested PCR assays with respect to early detection when the cutoff point is defined as more than 10 000 copies/ml. Moreover, treatment was required over a long period (30-60 days) when patients started antiviral therapy with a CMV copy number of more than 10 000 copies/ml. This long period of treatment might have serious effects with respect to cost, side effects and the appearance of drug-resistant virus strains.
In conclusion, our study indicates that the US17 region might be the most suitable genomic region to target using PCR. In addition, using real-time PCR on plasma, it is possible that CMV viral loads of 500 copies/ml might be the optimum cutoff value for initiating antiviral therapy in patients following SCT, receiving CMV immunoglobulin prophylaxis.
